Kokot F, Grzeszczak W, Wiecek A, Lao M, Gradowska L, Jagiełło R
Katedry i Kliniki Nefrologii Sl. AM, Katowicach.
Pol Arch Med Wewn. 1993 Mar;89(3):200-6.
Acute rejection is characterized by renal ischaemia which in turn is a triggering factor of EPO synthesis. On the other side during acute rejection (AR) the plasma PTH level (which is incriminated as an uraemic toxin) increases. This facts justified our present study which aimed to assess: 1. the influence of acute graft rejection (AR) on plasma EPO and PTH levels in KTP and 2. the influence of kind of antirejection therapy i.e. high dose of methylprednisolone (MP) vs thymoglobuline (TG) + moderate dose of methylprednisolone on plasma EPO and PTH levels respectively. A total of 28 KTP were studied who were divided into two groups: the first one designed as group MP comprised 17 KTP treated by high doses of MP while the second one designed as group ATG--consisted of 11 KTP treated by thymoglobulin+moderate doses of MP. The control group consisted of 16 healthy subjects. Before AR KTP showed inappropriately reduced EPO plasma levels when related to the degree of anaemia. AR was accompanied by a significant increase of plasma EPO and PTH levels in all examined KTP groups. After subsidence of AR normalization of plasma EPO and a significant decline of plasma PTH was noticed. A significant positive correlation was found between plasma EPO and PTH levels before the AR period in both examined groups.
急性排斥反应的特征是肾缺血,而肾缺血又是促红细胞生成素(EPO)合成的触发因素。另一方面,在急性排斥反应(AR)期间,血浆甲状旁腺激素(PTH)水平(被认为是一种尿毒症毒素)会升高。这些事实证明了我们目前的研究是合理的,该研究旨在评估:1. 急性移植排斥反应(AR)对肾移植后血浆EPO和PTH水平的影响;2. 不同抗排斥治疗方式,即高剂量甲泼尼龙(MP)与胸腺球蛋白(TG)+中等剂量甲泼尼龙对血浆EPO和PTH水平的影响。共研究了28例肾移植受者,分为两组:第一组为MP组,包括17例接受高剂量MP治疗的肾移植受者;第二组为ATG组,由11例接受胸腺球蛋白+中等剂量MP治疗的肾移植受者组成。对照组由16名健康受试者组成。在发生AR之前,肾移植受者的血浆EPO水平相对于贫血程度而言降低得不合理。在所有检查的肾移植受者组中,AR都伴随着血浆EPO和PTH水平的显著升高。AR消退后,血浆EPO恢复正常,血浆PTH显著下降。在两个研究组的AR期之前,血浆EPO和PTH水平之间发现显著正相关。